|
⚲
|
| Keyboard |
| Caligan Partners LP
✚
|
|
|---|---|
| CRD # | 289887 |
| SEC # | 801-113810 |
| CIK # | 0001727492 |
| AUM | 1,299.7 M (2026-05-29) |
| Employees | 5 (60% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 646-859-8204 |
| Address | 780 Third Avenue New York, NY 10017 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| In the News | |
|---|---|
| Wed, 20 May 2026 | Caligan Partners reports Liquidia stock transfer worth $317,894 — Investing.com |
| Mon, 13 Apr 2026 | List of Investments by Caligan Partners (Apr, 2026) — tracxn.com |
| Fees and Compensation — Form ADV Part 2A (5/29/2026) [Brochure] |
|---|
Item 5: Fees and Compensation
Caligan provides investment advisory services to the Funds pursuant to separate investment
advisory or consulting agreements (the “Agreements”). The Agreements for the Funds set forth in
detail the fee structure relevant to the Funds.
Caligan or its affiliates receive compensation and fees from the Funds based on a percentage of
assets under management and based on performance. Such compensation and fee arrangements
are set forth in the Agreements. As set forth in the Agreements, fees and compensation paid to
the Adviser or its affiliates by the Funds are either deducted from the assets of the Funds, or
separately paid by the Fund or its affiliates; asset-based fees are generally deducted on a quarterly
basis and performance-based compensation is deducted at the times set forth in the Agreements.
The Adviser or its affiliates may waive, reduce, or calculate differently the asset-based fees and
performance-based compensation for certain Investors or Funds, including members, employees
and affiliates of the Adviser.
Investment Distributions
A Partnership’s governing documents detail the amount and priority of distributions made by the
Partnership to its Investors (the “Investment Distributions”). Investment Distributions will include:
net cash proceeds from the sale of investments or any portion of an investment or marketable
securities available for distribution, and cash receipts from dividends, interest and other non-tax
distributions from investments net of expenses (“Current Income”). Investment Distributions will
be net of performance-based fees as detailed in a Partnership’s governing documents.
Organizational Expenses
A Partnership will bear all costs and expenses incurred in connection with the organization of the
Partnership, its general partner and if applicable each parallel partnership, including legal and
accounting fees, printing costs, travel and out-of-pocket expenses, and all costs and expenses
incurred in connection with the offering of interests in the Partnership (“Organizational
Expenses”).
Operating Expenses
A Partnership will be responsible for all expenses relating to its own operations and if applicable
the operations of each parallel partnership, including without limitation:
• Expenses related to the research, due diligence and monitoring of actual and prospective
investments (whether or not consummated) and the consummation of investments,
including the following: brokerage, prime brokerage and futures commission merchant
fees, commissions and expenses; expenses relating to short sales; clearing and settlement
charges; custodial fees and expenses; bank service fees; interest expenses and fees related
to financings or refinancings; fees and expenses of proxy research and voting services
(including proxy solicitors, investment bankers, public relations experts, and costs
associated with producing and distributing analyses and other materials); any
compensation paid to individuals (other than individuals that are employees or partners of
the Adviser) considered for nomination, nominated and/or appointed, to the board of a
company in which the Partnership is or was invested (including any compensation paid in
Page | 5
relation to serving in such capacity) and any related expenses (including costs incurred in
connection with recruiting such persons), it being understood that, to the extent that such
an individual is appointed to the board of such a company, it is generally expected that
such compensation would not be considered a Partnership expense and would be borne by
such company; fees and expenses of third-party professionals, including consultants,
investment bankers, attorneys and accountants; experts or other consultants engaged to
assist with an investment or prospective investment; investment and research-related travel
expenses (which are travel expenses incurred by the Adviser or their affiliates related to
the purchase or sale of, or due diligence regarding, the Partnership's investments, whether
or not such investments are consummated, including lodging and meals); and the costs of
any litigation or investigation involving activities of the Partnership.
• Operational expenses, including the following: fees and expenses relating to information
technology hardware, software or other technology (including costs of software licensing,
implementation, data management and recovery services and custom development) used
to research investments, evaluate and manage risk, facilitate valuations, facilitate
accounting functions, facilitate compliance with the rules of any self-regulatory
organization or applicable law (including reporting obligations), facilitate and manage the
order execution of financial instruments or otherwise manage the Partnership, such as
Bloomberg terminals, portfolio management systems, risk management systems and order
management systems; fees and expenses of third-party risk management products, models
and services; third-party administrative fees and expenses; fees and expenses of third-party
professionals, including consultants, valuation service providers, attorneys and
accountants; third-party audit and tax preparation expenses; 100% of the cost of insurance,
including premiums for cybersecurity insurance and liability insurance covering the
Adviser and its affiliates, and the members, partners, officers, employees and agents of any
of them; fees and expenses (including director registration fees) of the Partnership’s
... |
| Account Minimums and Types of Clients — Form ADV Part 2A (5/29/2026) [Brochure] |
|---|
Item 7: Types of Clients Caligan primarily provides discretionary investment management and advisory services to its Funds directly. Investors may include high net worth individuals, partnerships, pension funds and profit-sharing plans, trusts, estates, charitable organizations, corporations, business entities, endowments, investment funds and foreign sovereign wealth funds. Investors will be required to meet certain suitability qualifications to comply with applicable federal securities laws and regulations, specifically as the Funds will rely on exemption 3(c)(7) of the Investment Company Act. A Partnership requires minimum initial subscriptions from Investors as described in its offering documents. A Partnership may accept lower subscription amounts under the circumstances described in its offering document. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Liquidia Corp | 306.4 | ||
| Revolution Medicines Inc | 183.0 | ||
| Abivax Sa | 162.8 | ||
| Vaxcyte Inc | 119.7 | ||
| Xenon Pharmaceuticals Inc | 81.0 | ||
| Mineralys Therapeutics Inc | 75.1 | ||
| Exelixis Inc | 66.6 | ||
| CG Oncology Inc | 60.9 | ||
| BCTG Acquisition Corp | 50.4 | ||
| TYRA Biosciences Inc | 48.9 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Caligan Partners CV VII LP | 2024-03-28 | ||
| HF | Caligan Partners CV VI LP | [2024-03-28] | 14.6 M | 36.0 M |
| Filed 2024-05-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Caligan Partners CV IV LP | [2022-03-30] | 18.2 M | 175.6 M |
| Filed 2021-04-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Caligan Partners CV V LP | [2022-03-30] | 18.2 M | 9.6 M |
| Filed 2021-04-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Caligan Partners Master Fund LP | [2022-03-30] | 6.9 M | 812.0 M |
| Offered $6,946,060 · Filed 2025-08-15 (D/A) · Exemption 506(c) · Minimum $500,000 · Duration More than one year · Revenue $1,000,001 - $5,000,000 | ||||
| HF | Caligan Partners CV III LP | [2021-03-25] | 33.9 M | 42.2 M |
| Filed 2020-12-09 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Caligan Partners CV II LP | 2020-03-26 | 39.9 M | |
| HF | Caligan Partners CV I LP | [2019-02-04] | 19.0 M | 23.8 M |
| Filed 2019-01-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 8 | 1,299.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 8 | 1,299.7 |
| By Discretionary | ||
| Discretionary | 8 | 1,299.7 |
| Non-Discretionary | 0 | 0.0 |
| Total | 8 | 1,299.7 |
| By Non-United States Persons | ||
| Non-United States Persons | 666.7 | |
| United States Persons | 633.0 | |
| Total | 8 | 1,299.7 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Caligan Partners LP | Promoter | 6 | 2 | |
| Caligan Partners CV VI GP LLC | Executive Officer | 1 | 1 | |
| Samuel Merksamer | Executive Officer | 1 | 1 | |
| Caligan Partners CV IV GP LLC | Executive Officer | 1 | 1 | |
| Caligan Partners CV IV LP | Promoter | 1 | 1 | |
| Caligan Partners CV III GP LLC | Executive Officer | 1 | 1 | |
| Caligan Partners CV GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001727492] | |
| 3 | [0001727492] | |
| 4 | [0001727492] | |
| SC 13D | [0001727492] | |
| SC 13G | [0001727492] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional, Retail |
| Fund Types | Hedge Fund |
| LEI | 549300FWK7CGQ83RTY05 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Exelixis Inc EXEL
Common Stock
|
2025-11-25 | Buy | 27,532 | $43.12 | 1,187,180 |
|
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
|
2025-06-17 | Grant | 18,396 | $0.00 | |
|
Exelixis Inc EXEL
Option (right to buy) · derivative
|
2025-05-29 | Grant | 21,464 | $0.00 | |
|
Alimera Sciences Inc ALIM
"Common Stock, par value $0.01 per share (""Common Stock"")"
|
2024-09-16 | Other | 16,835,154 | ||
|
Alimera Sciences Inc ALIM
Warrants · derivative
|
2024-09-16 | Other | 800,000 | ||
|
Alimera Sciences Inc ALIM
Notional Derivative Agreements (obligation to buy) · derivative
|
2024-09-16 | Other | 1 | ||
|
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
|
2024-09-12 | Grant | 1,123,595 | $8.90 | 9,999,996 |
|
Liquidia Corp LQDA
Common Stock
|
2024-08-30 | Sell | 150,000 | $9.51 | 1,426,500 |
|
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
|
2024-08-30 | Other | 3,440,948 | ||
|
Liquidia Corp LQDA
Common Stock
|
2024-08-30 | Buy | 150,000 | $9.51 | 1,426,500 |
|
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
|
2024-06-20 | Grant | 20,359 | $0.00 | |
|
Exelixis Inc EXEL
Option (right to buy) · derivative
|
2024-05-31 | Grant | 42,767 | $0.00 | |
|
Exelixis Inc EXEL
Common Stock
|
2024-05-30 | Buy | 225,000 | $20.76 | 4,671,000 |
|
Exelixis Inc EXEL
Common Stock
|
2024-05-28 | Buy | 200,000 | $20.32 | 4,064,000 |
|
Exelixis Inc EXEL
Common Stock
|
2024-02-21 | Buy | 190,000 | $20.70 | 3,933,000 |
|
Liquidia Corp LQDA
"Common Stock, $0.001 par value per share (""Common Stock"")"
|
2023-12-14 | Buy | 1,117,318 | $7.16 | 7,999,997 |
|
Exelixis Inc EXEL
Common Stock
|
2023-11-27 | Buy | 120,409 | $21.61 | 2,602,038 |
|
Exelixis Inc EXEL
Common Stock
|
2023-11-27 | Sell | 120,409 | $21.61 | 2,602,038 |
|
Alimera Sciences Inc ALIM
Common Stock
|
2023-09-14 | Buy | 579,000 | $3.39 | 1,962,810 |
|
Alimera Sciences Inc ALIM
Notional Derivative Agreements (obligation to buy) · derivative
|
2023-09-14 | Other | 1 | ||
| showing 20 of 56 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Weatherbie Capital LLC
✚
|
MA | 1,343.1 M |
|
Coury Firm Asset Management LLC
✚
|
PA | 1,324.8 M |
|
Paragon Capital Management
✚
|
CO | 1,316.2 M |
|
Savoie Capital LLC
✚
|
IL | 1,315.0 M |
|
Synergy Asset Management LLC
✚
|
WA | 1,299.4 M |
|
New Legacy Group LLC
✚
|
NY | 1,283.7 M |
|
Private Capital Advisors Inc
✚
|
CT | 1,281.8 M |
|
L2 Asset Management LLC
✚
|
1,270.8 M | |
|
Zadig Asset Management Sa
✚
|
1,252.2 M | |
|
Arbiter Partners Capital Management LLC
✚
|
NY | 1,250.7 M |